Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/18/2014WO2014142219A1 Guanidinobenzoic acid ester compound
09/18/2014WO2014142146A1 Therapeutic agent for meibomian dysfunction
09/18/2014WO2014142127A1 Phenylxanthene derivative
09/18/2014WO2014142116A1 Ceramide-like function imparting agent
09/18/2014WO2014142113A1 Silica preparation containing cashew nut shell oil or the like
09/18/2014WO2014142092A1 Novel pi polyamide
09/18/2014WO2014142086A1 Pyrrolidin-3-yl acetate derivative and piperidin-3-yl acetate derivative
09/18/2014WO2014142056A1 Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
09/18/2014WO2014142012A1 Ophthalmic composition for soft contact lens
09/18/2014WO2014141847A1 Therapeutic agent for systemic bone disease and use thereof
09/18/2014WO2014141289A1 Photo - chemo composition on the basis of microcapsules with a core -shell structure
09/18/2014WO2014141288A1 The art, method, manner, process and system of a nano-biomineral for multi-modal contrast imaging and drug delivery
09/18/2014WO2014141287A1 The art, method, manner, process and system of multifunctional nanobiomaterial for molecular imaging and drug- delivery
09/18/2014WO2014141280A1 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
09/18/2014WO2014141261A1 Method for treatment of parkinson's disease
09/18/2014WO2014141218A1 Novel 1, 2, 4-oxadiazol compounds active against gram-positive pathogens
09/18/2014WO2014141194A2 Biomarker
09/18/2014WO2014141187A1 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
09/18/2014WO2014141177A1 New arylaminoalcohol derivatives with antiplasmodial activity
09/18/2014WO2014141175A1 Novel acrylamide derivatives as antimalarial agents
09/18/2014WO2014141171A1 Pyridin-4-yl derivatives
09/18/2014WO2014141165A1 Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
09/18/2014WO2014141153A1 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
09/18/2014WO2014141135A1 Respirable agglomerates of porous carrier particles and micronized drug
09/18/2014WO2014141132A1 NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
09/18/2014WO2014141127A1 Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
09/18/2014WO2014141118A1 Imidazo[4,5-c]quinoline derivatives and uses thereof
09/18/2014WO2014141110A2 Aminonitriles as kynurenine pathway inhibitors
09/18/2014WO2014141104A1 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
09/18/2014WO2014141091A1 Pyrrole derivatives as alpha 7 nachr modulators
09/18/2014WO2014141082A1 Agent for the prophylaxis and/or treatment of neoplastic diseases
09/18/2014WO2014141079A1 Compositions for use in treating eye disorders using dipyridamole
09/18/2014WO2014141069A1 Deamorphization of spray-dried formulations via spray-blending
09/18/2014WO2014141065A1 Azetidine amide derivatives as orexin receptor antagonists
09/18/2014WO2014141015A1 Pyrazolylbenzo[d]imidazole derivatives
09/18/2014WO2014140989A2 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
09/18/2014WO2014140988A1 Rifaximin for use in the treating of vaginal infections.
09/18/2014WO2014140929A1 Process for drying bendamustine hydrochloride monohydrate
09/18/2014WO2014140911A2 Diagnostic and therapeutic methods relating to microrna-144
09/18/2014WO2014140797A1 MicroRNA-BASED APPROACH TO TREATING MALIGNANT PLEURAL MESOTHELIOMA
09/18/2014WO2014140704A1 Indole compounds that activate ampk
09/18/2014WO2014140699A1 A novel process of liberation of erythromycin and preparation of its salts
09/18/2014WO2014140695A1 Solid oral formulation of a pyrrolidine substituted flavone compound
09/18/2014WO2014140680A1 Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
09/18/2014WO2014140671A1 New arylaminoalcohol derivatives with antiplasmodial activity
09/18/2014WO2014140648A1 Drug combination
09/18/2014WO2014140647A1 Drug combination
09/18/2014WO2014140644A1 Chemical entities
09/18/2014WO2014140631A1 Prx933 (prx-00933), a 5ht2c agonist, for use in the treatment of hypertension
09/18/2014WO2014140597A1 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
09/18/2014WO2014140592A1 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
09/18/2014WO2014140591A1 New compounds
09/18/2014WO2014140582A1 Kinase inhibitors
09/18/2014WO2014140581A1 Transcription factor decoys
09/18/2014WO2014140510A1 Pro-drug compounds
09/18/2014WO2014140411A1 Encapsulated composition for binding aldehydes in the stomach
09/18/2014WO2014140410A1 Composition for oral administration for binding aldehydes in the gastrointestinal tract
09/18/2014WO2014140402A1 Use of derivatives with c-o-p bonds in patients with renal failure
09/18/2014WO2014140365A1 Microbicidally active imidazopyridine derivatives
09/18/2014WO2014140321A1 Antiviral indolo[2,3-b]quinoxaline
09/18/2014WO2014140313A1 Macrocyclic salt-inducible kinase inhibitors
09/18/2014WO2014140312A1 Flavonoid-based composition for pharmaceutical, nutritional or cosmetic use having potentiated antioxidant action
09/18/2014WO2014140310A1 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
09/18/2014WO2014140299A1 Macrocyclic rip2 kinase inhibitors
09/18/2014WO2014140286A1 Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance
09/18/2014WO2014140284A1 Use of linagliptin in cardio- and renoprotective antidiabetic therapy
09/18/2014WO2014140279A1 Novel inhibitors
09/18/2014WO2014140246A1 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor
09/18/2014WO2014140241A1 Pyridine derivatives as dgat-1 inhibitors
09/18/2014WO2014140235A1 Macrocyclic lrrk2 kinase inhibitors
09/18/2014WO2014140217A1 Method for scheduling ovulation
09/18/2014WO2014140213A1 Taxoid - purification principle for liquid excipients
09/18/2014WO2014140203A1 Particles comprising luminescent lanthanide complexes
09/18/2014WO2014140186A1 Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
09/18/2014WO2014140184A1 Novel inhibitor compounds of phosphodiesterase type 10a
09/18/2014WO2014140159A1 Dosage form comprising crizotinib
09/18/2014WO2014140095A1 Injectable morphine formulations
09/18/2014WO2014140091A1 Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014WO2014140086A1 Novel inhibitor compounds of phosphodiesterase type 10a
09/18/2014WO2014140081A1 Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014WO2014140078A1 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014WO2014140077A1 Furopyridines as bromodomain inhibitors
09/18/2014WO2014140076A1 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
09/18/2014WO2014140075A1 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014WO2014140073A1 Process for making benzoxazepin compounds
09/18/2014WO2014140072A1 Etoposide and prodrugs thereof for use in targeting cancer stem cells
09/18/2014WO2014140065A1 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
09/18/2014WO2014140051A1 Mir-204 and mir-211 and uses thereof
09/18/2014WO2014139983A1 [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
09/18/2014WO2014139981A1 Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors
09/18/2014WO2014139978A1 New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
09/18/2014WO2014139970A1 Processes and intermediates for preparing a medicament
09/18/2014WO2014139894A1 Homoarginine as therapeutic for the reduction of myocardial remodeling
09/18/2014WO2014139882A1 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
09/18/2014WO2014139836A1 Pharmaceutical compositions comprising imatinib
09/18/2014WO2014139759A1 Compositions consisting of alkylamidothiazoles and uv-filter substances
09/18/2014WO2014139758A1 Compositions consisting of alkylamidothiazoles and aromatic substances
09/18/2014WO2014139681A1 Crystalline cis-(e)-4-(3-fluorophenyl)-2',3',4',9'-tetrahydro-n,n-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1h]-pyrido[3,4-b]indol]-4-amine
09/18/2014WO2014139677A1 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
09/18/2014WO2014139657A1 Pharmaceutical composition containing an oxazolidinone antibacterial agent and method for the preparation thereof
1 ... 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 ... 7860